ef1da23cbc The first patient was recruited in September 2000 and results should be available in 2006. Format: AbstractFormatSummarySummary (text)AbstractAbstract (text)MEDLINEXMLPMID ListApplySend toChoose DestinationFileClipboardCollectionsE-mailOrderMy BibliographyCitation managerFormatSummary (text)Abstract (text)MEDLINEXMLPMID ListCSVCreate File1 selected item: 15332386FormatSummarySummary (text)AbstractAbstract (text)MEDLINEXMLPMID ListMeSH and Other DataE-mailSubjectAdditional textE-mailDidn't get the message? Find out why.Add to ClipboardAdd to CollectionsOrder articlesAdd to My BibliographyGenerate a file for use with external citation management software.Create File See comment in PubMed Commons belowEur Respir J. NLM NIH DHHS USA.gov National Center for Biotechnology Information, U.S.. PubMed US National Library of Medicine National Institutes of Health Search databaseAll DatabasesAssemblyBioProjectBioSampleBioSystemsBooksClinVarCloneConserved DomainsdbGaPdbVarESTGeneGenomeGEO DataSetsGEO ProfilesGSSGTRHomoloGeneMedGenMeSHNCBI Web SiteNLM CatalogNucleotideOMIMPMCPopSetProbeProteinProtein ClustersPubChem BioAssayPubChem CompoundPubChem SubstancePubMedPubMed HealthSNPSparcleSRAStructureTaxonomyToolKitToolKitAllToolKitBookToolKitBookghUniGeneSearch termSearchAdvancedHelp . Cookies are required to use this site. Gov'tMeSH TermsAdministration, InhalationAdolescentAdultAgedAlbuterol/administration & dosage*Albuterol/analogs & derivatives*Androstadienes/administration & dosage*Dose-Response Relationship, DrugDouble-Blind MethodDrug Administration ScheduleDrug Therapy, CombinationFemaleFluticasoneFollow-Up StudiesHumansMaleMiddle AgedPulmonary Disease, Chronic Obstructive/diagnosisPulmonary Disease, Chronic Obstructive/drug therapy*Pulmonary Disease, Chronic Obstructive/mortality*Reference ValuesRespiratory Function TestsRisk AssessmentSalmeterol XinafoateSeverity of Illness IndexStatistics, NonparametricSurvival AnalysisSubstancesAndrostadienesSalmeterol XinafoateFluticasoneAlbuterolLinkOut - more resourcesFull Text SourcesHighWireOther Literature SourcesCOS Scholar UniverseMedicalClinicalTrials.govCOPD - MedlinePlus Health InformationMiscellaneousALBUTEROL - Hazardous Substances Data BankPubMed Commons home PubMed Commons 0 commentsHow to join PubMed CommonsHow to cite this comment: .
The primary end-point is all-cause mortality; secondary end-points are COPD morbidity relating to rate of exacerbations and health status, using the St George's Respiratory Questionnaire. Warning: The NCBI web site requires JavaScript to function. 2004 Aug;24(2):206-10.The TORCH (towards a revolution in COPD health) survival study protocol.Vestbo J1; TORCH Study Group.Author information1North West Lung Research Centre, Wythenshawe Hospital, Manchester, UK. Please review our privacy policy. Supplemental Content Full text links . HTTP Status 404 - . Your browser doesn't accept cookies. Some suggestions: Go back to the last page Go to the home page .. TORCH is a multicentre, randomised, double-blind, parallel-group, placebo-controlled study.
Kallogerol replied
471 weeks ago